Objective: In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. Methods: This study set up three groups: a control group; an Ang II group (Ang II 10 –6 mol/l, Sigma); and a losartan group (losartan 10 –6 mol/l, Sigma). We used RT-PCR assay to detect TRPC6 mRNA expression, and Western blot to detect TRPC6 protein expression. Results: TRPC6 overexpression was the basic change of podocyte injury and proteinuria occurrence. Losartan can treat podocyte injury and proteinuria induced by Ang II via downregulation of TRPC6 in podocytes. Conclusion: These findings maybe provide an ideal drug target for the diagnosis and treatment of acquired glomerular diseases.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)